Doxy-PEP (sometimes called “doxy prep”) is a strategy that uses a common antibiotic, doxycycline, to prevent bacterial sexually transmitted infections after sex. The idea is simple: you take a single 200 mg dose of doxycycline within 72 hours of having sex, and it kills the bacteria that cause chlamydia, syphilis, and gonorrhea before they can establish an infection. In clinical trials, it reduced chlamydia and syphilis infections by more than 70%. The CDC issued formal guidelines recommending it in 2024 for specific groups at higher risk.
How Doxy-PEP Works
Doxycycline is a tetracycline antibiotic that’s been around for decades. When you take it after a potential STI exposure, it reaches concentrations in body tissues and secretions that are 5 to 20 times higher than what’s needed to stop the bacteria responsible for syphilis, chlamydia, and gonorrhea from growing. Those levels stay effective for different durations depending on the bacteria: about 48 hours for gonorrhea, 72 hours for syphilis, and 96 hours for chlamydia.
This is why the 72-hour window matters. The drug works best when taken as soon after sex as possible, while bacterial counts are still low enough to be wiped out by a single dose. It’s a post-exposure approach, not a daily pill. You only take it when you’ve had a potential exposure.
Who It’s Recommended For
The CDC’s 2024 guidelines are specific about who should be offered doxy-PEP: gay, bisexual, and other men who have sex with men (MSM) and transgender women who have had at least one bacterial STI (syphilis, chlamydia, or gonorrhea) in the past 12 months. A provider should discuss the option through shared decision-making, then write a prescription so you can keep the medication on hand.
The guidelines don’t currently extend to cisgender women or heterosexual men. That’s not because doxycycline can’t work in those populations. Pharmacokinetic data suggests it reaches effective concentrations in vaginal tissue. The gap is in clinical trial evidence: the largest trials enrolled MSM and transgender women, so there isn’t yet strong enough data to make a broad recommendation for other groups. Researchers have noted that doxy-PEP should be assessed in these populations going forward.
How Effective It Is
Three large randomized controlled trials have tested doxy-PEP. The results are consistent: it works very well against chlamydia and syphilis, and less reliably against gonorrhea.
In the major U.S. trial, doxy-PEP produced an overall 65% reduction in bacterial STIs. Broken down by infection, chlamydia and syphilis each dropped by about 80%, while gonorrhea dropped by roughly 50%. A French trial called DOXYVAC found even more dramatic results for chlamydia and syphilis combined, with an 83% reduction. In that study, gonorrhea rates were not significantly affected.
Real-world data from San Francisco, where doxy-PEP was adopted early, showed citywide chlamydia rates about 50% lower than predicted and primary/secondary syphilis rates 51% lower than predicted. Gonorrhea rates did not decline compared to predictions. The pattern is clear: doxy-PEP is highly effective against chlamydia and syphilis but offers limited, inconsistent protection against gonorrhea.
The Dose and How to Take It
The protocol is straightforward. You take 200 mg of doxycycline (any formulation) as soon as possible after oral, vaginal, or anal sex, and no later than 72 hours afterward. You should not take more than 200 mg in any 24-hour period. So if you have sex on multiple consecutive days, you’d take one dose per day, not one dose per encounter.
A few practical tips make a difference. Take it with a full glass of water and stay upright for at least 30 minutes to an hour afterward. Doxycycline can irritate the esophagus if it gets stuck on the way down, causing chest pain or difficulty swallowing. Taking it with food can help reduce nausea.
Side Effects to Know About
Doxycycline is generally well tolerated, but it does have a predictable set of side effects. The most common are gastrointestinal: nausea, vomiting, and acid reflux. In the French DOXYVAC trial, about 2% of participants stopped taking doxy-PEP because of GI symptoms. For most people, taking it with food is enough to manage the discomfort.
Sun sensitivity is the other major concern. Doxycycline makes your skin more vulnerable to sunburn and UV damage. Sunscreen, limiting direct sun exposure, and avoiding tanning beds are all recommended while using it.
Rarely, doxycycline can cause increased pressure inside the skull, which shows up as persistent headaches or vision changes. This is uncommon but worth knowing about, since it requires prompt medical evaluation. Doxycycline is also contraindicated during pregnancy. Tetracycline antibiotics can stain developing teeth and potentially affect fetal bone growth when used during the second or third trimester.
The Antibiotic Resistance Question
The biggest concern about widespread doxy-PEP use isn’t a side effect you’d feel. It’s the potential for antibiotic resistance. Every time bacteria are exposed to an antibiotic without being fully eliminated, the survivors can develop resistance genes and pass them along.
Research from UCSF found that doxy-PEP did not significantly change the overall composition of gut bacteria. That’s reassuring. But it did increase the proportion of tetracycline resistance genes in gut microbes, and the effect was dose-dependent: the more doxy-PEP someone used, the more resistance genes accumulated. As one of the researchers put it, “It’s not totally innocuous.”
This matters because gonorrhea is already highly resistant to many antibiotics, and doxy-PEP’s weaker effectiveness against gonorrhea may partly reflect existing resistance. The CDC has acknowledged that antimicrobial resistance is a key area of ongoing monitoring. Their current approach is to limit doxy-PEP recommendations to the populations where the benefit is most clearly proven, which minimizes unnecessary antibiotic exposure while still protecting the people at highest risk.
How It Compares to PrEP for HIV
If you’re familiar with PrEP for HIV prevention, doxy-PEP follows a similar logic but with important differences. HIV PrEP is typically taken daily (or, with some regimens, around the time of sex) to prevent a viral infection. Doxy-PEP is taken only after sex and targets bacterial infections. It does nothing to prevent HIV, herpes, HPV, or other viral STIs.
Many people who use doxy-PEP are already on HIV PrEP or living with HIV. In the clinical trials, participants were either HIV-negative and taking PrEP or HIV-positive and on treatment. Doxy-PEP adds a layer of bacterial STI protection on top of whatever viral prevention strategy someone already has in place. It’s a complement, not a replacement.
Getting a Prescription
Doxy-PEP requires a prescription. You can ask your primary care provider, a sexual health clinic, or an infectious disease specialist. The conversation typically involves reviewing your STI history from the past year and discussing whether doxy-PEP makes sense for your situation. The prescription is written so you can keep doxycycline on hand and self-administer it when needed, rather than needing to visit a clinic after every encounter.
Regular STI screening remains important while using doxy-PEP. The protection isn’t 100%, particularly for gonorrhea, so routine testing helps catch any infections that break through. Most providers will recommend screening every three to six months, consistent with standard guidelines for people at higher STI risk.